---
title: Luspatercept
description: 'Luspatercept is prescribed for the treatment of anemia in adults with:'
is_banned: false
lastModified: '2025-09-22T17:21:53.539Z'
faqs:
  - q: >-
      What is the recommended dosage for Luspatercept?**


      **A:**  The initial dose is 1 mg/kg subcutaneously every 3 weeks, with
      titration up to 1.25 mg/kg in beta-thalassemia and 1.75 mg/kg in MDS based
      on response and tolerance.
    a: >-
      A:**  The initial dose is 1 mg/kg subcutaneously every 3 weeks, with
      titration up to 1.25 mg/kg in beta-thalassemia and 1.75 mg/kg in MDS based
      on response and tolerance.
  - q: >-
      How does Luspatercept differ from erythropoiesis-stimulating agents
      (ESAs)?**


      **A:** Luspatercept acts later in erythroid maturation than ESAs,
      specifically targeting later-stage precursors.
    a: >-
      A:** Luspatercept acts later in erythroid maturation than ESAs,
      specifically targeting later-stage precursors.
  - q: >-
      Can Luspatercept replace blood transfusions entirely?**


      **A:** While it can significantly reduce the need for transfusions, it may
      not eliminate them completely in all patients.  It's not a substitute for
      urgent transfusion needs.
    a: >-
      A:** While it can significantly reduce the need for transfusions, it may
      not eliminate them completely in all patients.  It's not a substitute for
      urgent transfusion needs.
  - q: |-
      What are the most common side effects?**

      **A:** Headache, bone pain, arthralgia, fatigue are commonly reported.
    a: 'A:** Headache, bone pain, arthralgia, fatigue are commonly reported.'
  - q: >-
      What are the serious side effects to watch for?**


      **A:**  Thromboembolic events and hypertension are serious potential side
      effects.
    a: >-
      A:**  Thromboembolic events and hypertension are serious potential side
      effects.
  - q: >-
      Is Luspatercept safe in pregnancy?**


      **A:** No. It is contraindicated in pregnancy due to evidence of
      teratogenicity in animal studies.
    a: >-
      A:** No. It is contraindicated in pregnancy due to evidence of
      teratogenicity in animal studies.
  - q: >-
      How should Luspatercept be administered?**


      **A:**  It is administered as a subcutaneous injection by a healthcare
      professional.
    a: >-
      A:**  It is administered as a subcutaneous injection by a healthcare
      professional.
  - q: >-
      Can Luspatercept be used in children?**


      **A:**  No, Luspatercept is not approved for use in patients under 18
      years of age.
    a: >-
      A:**  No, Luspatercept is not approved for use in patients under 18 years
      of age.
  - q: >-
      What monitoring is required during Luspatercept treatment?**


      **A:**  Monitor hemoglobin levels before each dose, blood pressure
      regularly, and assess for signs and symptoms of thromboembolism.
    a: >-
      A:**  Monitor hemoglobin levels before each dose, blood pressure
      regularly, and assess for signs and symptoms of thromboembolism.
  - q: >-
      How long should a patient continue treatment with Luspatercept?**


      **A:** Treatment should be continued as long as the patient experiences
      clinical benefit. Discontinue if there is no response after reaching the
      maximum dose for a specified period.
    a: >-
      A:** Treatment should be continued as long as the patient experiences
      clinical benefit. Discontinue if there is no response after reaching the
      maximum dose for a specified period.
---
## **Usage**

Luspatercept is prescribed for the treatment of anemia in adults with:

* **Beta-thalassemia:**  Specifically, patients who require regular red blood cell (RBC) transfusions.
* **Myelodysplastic Syndromes (MDS):**  In two specific scenarios:
    * Patients with very low- to intermediate-risk MDS who are transfusion-dependent and have not been previously treated with an erythropoiesis-stimulating agent (ESA).
    * Patients with very low- to intermediate-risk MDS who are transfusion-dependent (requiring at least two RBC units over 8 weeks), have ring sideroblasts (RS+), and have either failed erythropoietin-based therapy or are unsuitable for it.

**Pharmacological Classification:** Erythroid maturation agent.

**Mechanism of Action:** Luspatercept promotes late-stage red blood cell maturation by binding to and sequestering select TGF-β superfamily ligands, including growth differentiation factor 11 (GDF11), thus inhibiting Smad2/3 signaling, reducing apoptosis and promoting differentiation of erythroid progenitors.

## **Alternate Names**

Generic Name: Luspatercept-aamt

Brand Name: Reblozyl

## **How It Works**

**Pharmacodynamics:** Luspatercept promotes late-stage red blood cell maturation, ultimately decreasing the need for red blood cell transfusions in eligible patients.

**Pharmacokinetics:**

* **Absorption:**  Administered subcutaneously, Luspatercept reaches peak serum concentrations within approximately 1 to 3 days.
* **Metabolism:**  Presumed to be catabolized into amino acids like other proteins.
* **Elimination:**  Primarily eliminated through protein degradation processes in multiple tissues. The terminal half-life is approximately 11 to 15 days.


**Mode of Action:**  Luspatercept binds to members of the transforming growth factor-beta (TGF-β) superfamily, including GDF11, preventing these ligands from interacting with their receptors. This inhibition of Smad2/3 signaling promotes erythroid maturation.

**Elimination Pathways:** Protein degradation with subsequent amino acid excretion.


## **Dosage**

### **Standard Dosage**

#### **Adults:**

* **Initial Dose:** 1 mg/kg subcutaneously once every 3 weeks.
* **Dose Titration:**
    * For beta-thalassemia: If no reduction in RBC transfusion burden after at least 2 consecutive doses (6 weeks) at 1 mg/kg, increase to 1.25 mg/kg every 3 weeks.  If no reduction after 3 doses (9 weeks) at 1.25 mg/kg, discontinue treatment.
    * For MDS: If no reduction in RBC transfusion burden after at least 2 consecutive doses (6 weeks) at 1 mg/kg, increase to 1.33 mg/kg every 3 weeks.  If no reduction after at least 2 consecutive doses at 1.33 mg/kg, increase to 1.75 mg/kg every 3 weeks. Discontinue if no benefit after 3 doses at the maximum dose.

* **Maximum Dose:** Beta-thalassemia: 1.25 mg/kg. MDS: 1.75 mg/kg.


#### **Children:** No established dosing guidelines. Luspatercept is not recommended for pediatric patients under 18 years of age.

#### **Special Cases:**

* **Elderly Patients:** No initial dose adjustment is required.
* **Patients with Renal Impairment:** No dose adjustment required for mild to moderate impairment. No data available for severe impairment.
* **Patients with Hepatic Dysfunction:** No dose adjustment required.
* **Patients with Comorbid Conditions:** Monitor closely, especially those with hypertension or a history of thromboembolic events.


### **Clinical Use Cases**

Luspatercept is not intended for use in acute settings like intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations. It is meant for chronic anemia management.

### **Dosage Adjustments**

Dose adjustments should be made no more frequently than every 6 weeks.  Dose reductions may be necessary for managing side effects.


## **Side Effects**

### **Common Side Effects:**

Headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, dizziness, nausea.

### **Rare but Serious Side Effects:**

Thromboembolic events (including venous thromboembolism and pulmonary embolism), hypertension, hypersensitivity reactions.

### **Long-Term Effects:**

Potential long-term effects are still being evaluated.

### **Adverse Drug Reactions (ADR):**

Severe thromboembolic events, severe hypersensitivity reactions, uncontrolled hypertension.

## **Contraindications**

Hypersensitivity to luspatercept, pregnancy.

## **Drug Interactions**

Limited clinically significant drug interactions have been reported. Iron-chelating agents do not appear to affect luspatercept pharmacokinetics.

## **Pregnancy and Breastfeeding**

**Pregnancy Safety Category:**  Contraindicated in pregnancy.  Luspatercept has shown teratogenic effects in animal studies.

**Breastfeeding:**  It is unknown if luspatercept is excreted in human milk.  Breastfeeding is not recommended during treatment and for 3 months after the last dose.

## **Drug Profile Summary**

* **Mechanism of Action:**  Promotes late-stage erythroid maturation by inhibiting select TGF-β superfamily ligands, particularly GDF11.
* **Side Effects:** Headache, bone pain, fatigue, thromboembolism, hypertension.
* **Contraindications:**  Hypersensitivity, pregnancy.
* **Drug Interactions:** Limited reported interactions.
* **Pregnancy & Breastfeeding:** Contraindicated in pregnancy; breastfeeding not recommended.
* **Dosage:**  1 mg/kg subcutaneously every 3 weeks, titratable up to 1.25 mg/kg (beta-thalassemia) or 1.75 mg/kg (MDS).
* **Monitoring Parameters:** Hemoglobin levels, blood pressure, signs of thromboembolism.

## **Popular Combinations**

Often used with best supportive care, which may include transfusions when necessary.  It is important to note that luspatercept is *not* a substitute for transfusions when immediate anemia correction is required.

## **Precautions**

* **General Precautions:** Monitor blood pressure and assess for signs and symptoms of thromboembolism before each administration.
* **Specific Populations:** See "Dosage" section.
* **Lifestyle Considerations:**  Counsel patients about the importance of adhering to prescribed contraception during treatment and for 3 months after the last dose if of childbearing potential.

## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Luspatercept?**

**A:**  The initial dose is 1 mg/kg subcutaneously every 3 weeks, with titration up to 1.25 mg/kg in beta-thalassemia and 1.75 mg/kg in MDS based on response and tolerance.

### **Q2: How does Luspatercept differ from erythropoiesis-stimulating agents (ESAs)?**

**A:** Luspatercept acts later in erythroid maturation than ESAs, specifically targeting later-stage precursors.

### **Q3: Can Luspatercept replace blood transfusions entirely?**

**A:** While it can significantly reduce the need for transfusions, it may not eliminate them completely in all patients.  It's not a substitute for urgent transfusion needs.

### **Q4: What are the most common side effects?**

**A:** Headache, bone pain, arthralgia, fatigue are commonly reported.

### **Q5: What are the serious side effects to watch for?**

**A:**  Thromboembolic events and hypertension are serious potential side effects.

### **Q6: Is Luspatercept safe in pregnancy?**

**A:** No. It is contraindicated in pregnancy due to evidence of teratogenicity in animal studies.

### **Q7:  How should Luspatercept be administered?**

**A:**  It is administered as a subcutaneous injection by a healthcare professional.

### **Q8: Can Luspatercept be used in children?**

**A:**  No, Luspatercept is not approved for use in patients under 18 years of age.

### **Q9: What monitoring is required during Luspatercept treatment?**

**A:**  Monitor hemoglobin levels before each dose, blood pressure regularly, and assess for signs and symptoms of thromboembolism.

### **Q10: How long should a patient continue treatment with Luspatercept?**

**A:** Treatment should be continued as long as the patient experiences clinical benefit. Discontinue if there is no response after reaching the maximum dose for a specified period.
